Iomai ---A short Take
Iomai's ipo came at 7$/Share. It's main tech is Trans cut Immunisation. Partnerships and also invested by Medi and Elan. pipeline incl TCI for influenza, travellers diarrhea and anthrax. Proof of efficacy shown both for travellers diarrhea and influenza. Also tci works for BCG vaccine and small pox.
But for elderly only TCI may not work that effectively because It's known that the elderly have weaker responses to flu immunization. So they plan to study intradermal injection, combined with other technologies such as co-administration of a patch containing an immune stimulant, could serve the dual purpose of dose-sparing and improving the immune response in the elderly.
Tech is novel and many players will be interested if they show good phase 2 results and might venture into other vaccines for kids in the future...
1) Since it is a patch on skin(TCI route) you don't need to see a doctor or a nurse to get the vaccination which is convenient for kids. It is pain free.
2) It requires very much lower dosage for immunisation, so flu vaccine can be stretched to more incase of pandemics.
3) A transdermal vaccination followed by a skin patch boosts the immunity in adults which is poor with normal influenza vaccine in adults.
4) Formulations stable outside cold chain.
Today's news:
Iomai Corporation Receives Award From NIH for Pandemic Flu Vaccine Research
- Company Benefits from $1.4 M Grant to Develop Needle-free Flu Booster -
GAITHERSBURG, Md., March 9 /PRNewswire-FirstCall/ -- Iomai Corp. (Nasdaq: IOMI), a biopharmaceutical company, received a $1.4 Million award from the National Institutes of Health (NIH) for the continued development of its immunostimulant (IS) needle-free patch to extend the availability of existing stocks of influenza vaccine in the case of a pandemic. The award from the National Institute of Allergy and Infectious Diseases is the second installation of a two-year, $2.9 Million grant first announced in January 2005. The grant was awarded under the government's biodefense initiative: "Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and SARS."
phx.corporate-ir.net
Dr.Praveen |
